SCHEMBL30217692

SCHEMBL30217692

COC(=O)c1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)c2ccc(C)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.43
SLC2A1 P11166 1/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TSHR P16473 1/20 0.42
SMPD3 Q9NY59 1/20 0.42
NR1H2 P55055 1/20 0.42
MAP4K4 O95819 1/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
PTPN11 Q06124 1/20 0.41
EED O75530 1/20 0.40
RBBP4 Q09028 1/20 0.40
SUZ12 Q15022 1/20 0.40
EZH2 Q15910 1/20 0.40
AEBP2 Q6ZN18 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25096832 1.00 BACE1 (0.43) BACE1SLC2A1MAPTMEN1KMT2A
SCHEMBL30217575 0.89 CKS1B (0.44) BACE1SLC2A1MAPTMEN1KMT2A
SCHEMBL25096858 0.89 CKS1B (0.44) BACE1SLC2A1MAPTMEN1KMT2A
SCHEMBL25096826 0.88 BACE1 (0.42) BACE1SLC2A1MAPTSMN1; SMN2SMPD3
SCHEMBL30217688 0.88 BACE1 (0.42) BACE1SLC2A1MAPTSMN1; SMN2SMPD3
SCHEMBL30312627 0.84 SMARCA2 (0.42) BACE1SLC2A1MAPTMEN1KMT2A
SCHEMBL4185271 0.84 MEN1 (0.44) BACE1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL2878919 0.84 MAP4K4 (0.43) BACE1SLC2A1MAPTMEN1KMT2A
SCHEMBL29256966 0.83 BACE1 (0.41) BACE1SLC2A1MAPTMEN1KMT2A
SCHEMBL30217876 0.83 BACE1 (0.41) BACE1SLC2A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
CN-118234724-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-06-21 CN disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 BACE1 668/4885SLC2A1 3908/4885MAPT 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.